secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001157523-23-001254
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum reports Q2 revenue $37.5M, LIVMARLI sales $32.5M; acquires CHENODAL/CHOLBAM for $210M
--------------------------------------------------------------------------------

- Q2 total revenue $37.5M (incl $5M license); LIVMARLI net sales $32.5M, up 86% YoY.
- Acquiring CHENODAL and CHOLBAM from Travere for $210M upfront + up to $235M milestones.
- Entered $210M private placement to fund acquisition; closed $316.3M convertible notes at 4% due 2029.
- Pipeline readouts H2 2023: EMBARK (biliary atresia), volixibat PSC/PBC, CHENODAL RESTORE.
- Cash $330M as of June 30; repurchased 9.75% royalty obligation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000115752323001254/0001157523-23-001254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000115752323001254/a53507837.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer